Hemogenyx Pharmaceuticals Share Discussion Threads

[tomboyb] 29/11/2021 08:28

Taken a few today -

[badger60] 27/11/2021 01:24

New variant must = a quid a share.

[luckyabbeygale] 26/11/2021 08:53

Should go back to at least 5p with these new variants. Last time we went up to 16p.

[david gruen] 26/11/2021 08:47

Hemo doing anything in the COVID space?

[badger60] 26/11/2021 08:43

Yes...10.5mio at 30 June...paid Orgenesis 1.6 Mio......6months cash burn circa 4mio going by half year results. Now still have to pay Penn and new premises....so circa 5mio cash left.

[justaman] 25/11/2021 14:55

https://twitter.com/justamantrading/status/1463872386525286401?s=21

[badger60] 25/11/2021 04:44

I can't see how the repayment of a 2.1 Mio loan warrants a PX rise or anything to get excited about. An update about cash in the bank would be useful, along with the rental cost of the new Mint office. My guess is that there's about 5 Mio cash left.

[ccr1958] 24/11/2021 15:39

Good RNS,interest building ..

[ashleyjv] 24/11/2021 15:30

"The Company continues to make rapid progress with its product candidates and retains a substantial cash balance that will enable it to continue its product development as planned."

[david gruen] 24/11/2021 15:26

Hemogenyx Pharmaceuticals PLC

24 November 2021

24 November 2021

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Convertible Loans Repayment

As originally announced in October 2018, Hemogenyx-Cell S.A. ("Hemogenyx-Cell") and Immugenyx LLC ("Immugenyx"), each wholly-owned subsidiaries of Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, each entered into separate convertible loan notes (the "Notes") with Orgenesis, Inc. ("Orgenesis"). The Company announces that each of Hemogenyx-Cell and Immugenyx have now repaid the respective loans pursuant to the terms of the Notes. The total sum in principal and interest repaid was $2,110,761.00.

[luckyabbeygale] 24/11/2021 15:07

Wow that is massive news from HEMO.
No more worry about dilution.
At least I will be getting my 1.9p average back and more.

[catsan] 19/11/2021 10:27

Good morning Alan, lets hope it never comes to that Dr Sandler is devoted to saving lives and will strive to get this into patients as soon as possible if the company was acquired and split up the work could be set back years which would be a disgrace. Whilst there is money to be made if your ruthless enough to buy it and split I believe in humanity and dont think anyone would be immoral enough to do it.

[alaneagle] 18/11/2021 16:39

Didn't realise that, Target. You might have thought there data would be correct as I did. Notwithstanding that I wonder what the breakup value is?

[on target] 18/11/2021 12:03

ADVFN market cap figure is out by a factor of 2. There are approx 1B shares in issue, so it's around £18M market cap.

[alaneagle] 18/11/2021 11:56

I now have a full position here. It strikes me that with a Market Cap of less than £10m, that some of the acquisition boys or companies they have dealings with might take a closer look at it. At the current valuation there would be money to be made in splitting it up and selling the pieces. Or, getting rid of the dead wood holding the company back and installing a more progressive management team.

[badger60] 18/11/2021 03:53

I note with interest that Dr. Walt's only has a one year contract which ends July 2222. Looks like he is actually being paid some in cash, and the rest in 3.1mio options.......no mention of the strike price.(25p?).
He has a CV like General Patton in WW2....been everywhere and done it all.
Unfortunately since his tenure no progress has been made except for Vlads regurgitated interview and a recent vid showing that they own a laptop, and what looks like a top of the range blender for the physically challenged.
Does anybody know what this bloke has actually done to increase share value, as the share price is more than 15% down since his employment in July.



"July 2021 the Company appointed Dr Alan E. Walts to the roles of Business Advisor and Board Observer. Dr Walts is a US-based Venture Partner with Advent Life Sciences, and previously accumulated over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013, Dr Walts most recently managed Genzyme's corporate venture fund, Genzyme Ventures (now Sanofi Ventures). Following Genzyme's landmark sale to Sanofi, he served as a business advisor to founding Chairman and CEO of Genzyme Henri Termeer from 2013-2017, and worked closely with Henri on founding and investing in early-stage companies. Dr Walts received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School. The Company entered into a Consulting Agreement with Dr Walts for a 12 month period of service which includes cash compensation and approximately 3,100,000 options.

[natty27] 17/11/2021 21:01

anyone buying at these levels will see a very healthy profit come the new year in my opinion. Time to buy is now while it's low. The IND license in Jan/Feb for clinical trials will propel the share price

[luckyabbeygale] 17/11/2021 15:49

Nice intraday breakout. Just need news now.

[on target] 16/11/2021 10:57

Mad Vlad and his home-made lab.

[badger60] 16/11/2021 10:54

MadVlads next vid is all about making Russian paper aeroplanes.

[badger60] 16/11/2021 09:21

Short note to Ssccss on LSE......shares can trade below their par value.(Hemo already has done In the early days before the covid spike).If a par value of a share is1p....the market price could be .001p...or even lower.